West German Study Group

This study looks at whether a combination of ribociclib (a targeted drug) and hormone therapy can help women with intermediate-risk, hormone receptor-positive, HER2-negative early breast cancer better than standard chemotherapy. About 1,684 women will take part. The goal is to se…

This study is for women with a common type of breast cancer (HR+/HER2-) who have a high chance of the cancer returning after initial treatment. It tests whether adding the drug abemaciclib to standard hormone therapy works better than hormone therapy alone to prevent cancer from …

This study tests whether a newer, targeted drug (T-DXd) works better than the usual chemotherapy cocktail for women with early-stage HER2-positive breast cancer. About 402 participants will receive either T-DXd or standard chemo before surgery. The goal is to see if T-DXd leads t…